Mirogabalin inhibits scratching behavior of spontaneous model mouse of atopic dermatitis
Frontiers in Pharmacology · 26.06.2024 · 15
DOI: 10.3389/fphar.2024.1382281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.06.2024. Verfasst von Kosuke Matsuda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Daiichi-Sankyo.
Abstract (Originalsprache)
Introduction
Atopic dermatitis (AD) is one of the most prevalent intractable chronic itch diseases worldwide. In recent years, new molecular-targeted drugs have emerged, but side effects and economic challenges remain. Therefore, since it is important for AD patients to have a wider range of treatment options, it is important to explore new therapeutic agents. Gabapentinoids, gabapentin and pregabalin, have been shown to be effective for the clinical treatment of several chronic itch. Recently, mirogabalin (MGB) was developed as a novel gabapentinoid. MGB is a drug for neuropathic pain and has a margin of safety between its side effects and the analgesic effect for animal experiments. Herein, we showed that MGB exhibited an antipruritic effect in a mouse model of AD using NC/Nga mice. Methods and results: The oral administration of MGB (10 mg/kg) inhibited spontaneous scratching behavior in AD mice and its effect was dose dependently. Then, when MGB (10 mg/kg) was orally administrated to healthy mice, it did not affect motor function, including locomotor activity, wheel activity, and coordinated movement. Moreover, gabapentin (100 mg/kg) and pregabalin (30 mg/kg), inhibited spontaneous scratching behavior in AD mice and decreased motor function in healthy mice. Furthermore, intracisternal injection of MGB (10 μg/site) significantly suppressed spontaneous scratching behavior in AD mice.
Discussion
In summary, our results suggest that MGB exerts an antipruritic effect via the spinal dorsal horn using NC/Nga mice. We hope that MGB is a candidate for a novel therapeutic agent for AD with relatively few side effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Japan.
- R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
- Daiichi-Sankyo
Zitieren
APA
Matsuda, K., Kitano, Y., Sawahata, M., Kume, T., & Uta, D. (2024). Mirogabalin inhibits scratching behavior of spontaneous model mouse of atopic dermatitis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1382281
Vancouver
Matsuda K, Kitano Y, Sawahata M, Kume T, Uta D. Mirogabalin inhibits scratching behavior of spontaneous model mouse of atopic dermatitis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1382281
BibTeX
@article{Matsuda2024,
author = {Matsuda, Kosuke and Kitano, Yutaka and Sawahata, Masahito and Kume, Toshiaki and Uta, Daisuke},
title = {Mirogabalin inhibits scratching behavior of spontaneous model mouse of atopic dermatitis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1382281}
}
EUVIMED